Local Pass Conference Innovative Local Approaches towards New Trends in Psychoactive Substance Use “Time to Rethink our Policy on Drugs - Effective Drug.

Slides:



Advertisements
Similar presentations
TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.
Advertisements

Zonta International Safe Cities for Women Project in Guatemala City and San Salvador a project in cooperation with United Nations Development Fund for.
HIV in Europe Stockholm, 3.November 2009 Communication on combating HIV/AIDS in the EU and the neighbourhood - strategy and second action plan ( )
Harm Reduction for Young People: Why A Youth Network? Diane Riley, PhD Canadian Foundation for Drug Policy, Youth Network for Harm Reduction & University.
STATEMENT BY THE MINISTER OF STATE FOR ETHICS AND INTEGRITY, OFFICE OF THE PRESIDENT UGANDA AT THE 4 TH IAACA ANNUAL SEMINAR DALIAN, CHINA 25 TH TO 28.
 Centre for Drug Misuse Research Glasgow Scotland From Harm Reduction to Abstinence: A Journey in Drug Treatment Pol From Harm Reduction to Abstinence:
Bylaw on drug demand reduction in Serbia. Bylaw(s) - principles  should be based on existing law(s)  should complement existing laws  should not be.
Beyond 2008: A global NGO review of the United Nations General Assembly Special Session on Illicit Drugs (UNGASS) AND As it may.
Overview of the 2010 work programme Paul Griffiths, Roland Simon, Rosemary de Sousa Scientific Committee meeting, Lisbon, November 2009.
Harmonizing public health and public safety in a politically conservative environment Joëlle Rabot Field Coordinator Collectif Urgence.
ARQ part II data management Training pack 2: Monitoring drug abuse for policy and practice.
Information needs for effective drug policy in the programme of the CZ PRES Identifying Europe’s information needs for effective drug policy Lisbon /
Key priorities, challenges and opportunities to advance the agenda for children in middle income countries of CIS, Eastern and Southern Europe Yuri Oksamitniy.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.
Canada’s Drug Strategy. 2 Purpose Provide an overview of Canada’s renewed National Drug Strategy  Historical context  Impetus for change  Renewed National.
Kazakhstan Gulnara Darbekova (1), Nadezhda Kozachenko (1), Irina Mingazova (1), Alexander Solodov (1), Natalia Kartashova (1), Zita Lazzarini (2,3), Patricia.
National Bureau for Drug Prevention How to improve quality of treatment services: the perspectives of Pompidou Group Piotr Jabłonski Director of National.
An EMCDDA view on recovery Roland Simon Head of Unit Intervention, Best Practice, and Scientific Partners.
Municipal Drug Policy Legislation, institutions and programs Assoc. Prof. Hristo Bozov, MD, PhD Deputy-Mayor of Municipality of Varna Chairman of Municipal.
Encuentro de Líderes Latinoamericanos con la Federación Mundial Contra Las Drogas MIÉRCOLES 3 DE DICIEMBRE DE 2014, BUENOS AIRES Sven-Olov Carlsson, International.
Effective Drugs Policy and Harm Reduction in Tanzania
Harm Reduction.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Annual report 2010: the state of the drugs problem in Europe.
Overview of Drug Control in Foreign Countries. Drug Control in EU A. Policy Trends ■ Decriminalisation of possession of small amount of drugs for personal.
Medical Professionalism and its Relationship to Public Health: Physician Advocacy and State Public Health Policy Thomas Kellogg Program Officer and Advisor.
Alcohol policy in Catalonia Joan Colom Antoni Gual Lidia Segura March 2007, Pécs, Baranya (H)
The British vs. American Models in history Drug addiction is illness Drug addiction is illness Medical model: based on controlled dispensation of drugs.
Peter Sarosi Hungarian Civil Liberties Union (HCLU) Dialogoue on Drug Policy 8 June, European and Hungarian drug policies: based on evidence?
Washington D.C., USA, July 2012www.aids2012.org Human rights as a key component of harm reduction strategy targeting people using drugs in Morocco.
Twinning Project Implementation of Strategy for Fight Against Drugs in Serbia Kick off and Assessment November 2012 Belgrade.
Australia’s Drug Policy Greg Denham Nossal Institute for Global Health.
Operationalizing structural programming for HIV/AIDS prevention and treatment James Hargreaves Centre for the Evaluation of Public Health Interventions.
European Commission Introduction to the Community Programme for Employment and Social Solidarity PROGRESS
Paul Griffiths and Roland Simon Wrap-up presentation What has the EMCDDA learned ?
HARM REDUCTION Bogotá November 2008 The Czech Republic in the heart of Europe.
ROMANIA MINISTRY OF HEALTH GENERAL DIRECTORATE OF PUBLIC HEALTH Health Promotion Unit Cristina Padeanu, MSc.
A Strategic Research Agenda for Europe in the field of illicit drugs Priorities for socio-economic and humanities research HDG Brussels - December 10,
Meeting of Caribbean National Drug Observatories CICAD Programme to Estimate the Human Social and Economic Cost of Drugs in the Americas (Cost Programme)
October 8 & 9 th, 2008 Conference on the Economy (COTE) University of the West Indies Programme Management Office Ministry of Planning, Housing and the.
EU model – evidence based Out of 100% of people who tried drugs, only 10% get to chronicle stage Out of 100% of people who tried drugs, only 10% get to.
„ Roma and Drugs in Figures – the Czech Republic“ Budapest, October 2004 Czech National Focal Point for Drugs and Drug Addiction Office of the Government.
Close to Nature Forestry and Forest Policy Challenges in Europe Ilpo Tikkanen, European Forest Institute Zvolen, Slovakia October, 2003 Together.
Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.
Social and medical care of intravenous drug users in the Central Bohemian Region Czech Republic PhDr. Pavla Doležalová regional anti-drug coordinator.
MODULE 2 Effective drug policy What needs to change?
Citywide Drugs Crisis Campaign 20 years experience of Community Involvement – Key Lessons for the next National Drugs Strategy 12 TH NOVEMBER 2015.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
1 Background & history of the debate Geneva, 14 October 2009 Ralf Jürgens.
Social rehabilitation and reintegration of drug addicts in community – experience from EU Dr. Josef Radimecký, Ph.D., MSc. UN International Day against.
1 THE POLITICAL ECONOMY OF DRUG TRAFFICKING INTRODUCTION 1. Pervasiveness of issue 2. Typicality? Or an extreme case? 3. Categorizing “illicit drugs”—
International Land Coalition Advancing the Monitoring of Land Governance for Ensuring Impact on Poverty Reduction Annalisa Mauro.
CDA: May CENTRAL DRUG AUTHORITY MANDATE A PRESENTATION TO THE PARLIAMENTARY PORTFOLIO COMMITTEE ON SOCIAL DEVELOPMENT PART 2.
First European conference on drug supply indicators, , Brussels – Feed-back Chloé Carpentier, Laurent Laniel, EMCDDA 33 rd meeting of the.
Implementation Science: Finding Common Ground and Perspectives Laura Reichenbach, Evidence Project, Population Council International Conference on Family.
Peculiarities of alcoholism prevalence in Russia and measures to reduce alcohol abuse Eugenia A. Koshkina Director, National Research Center on Addictions,
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
‘The War on Drugs: Failures, Impacts, and Alternatives, and the Future of Public Health’ Niamh Eastwood Release 15 November 2014.
Harm reduction evidence: Eastern Europe and Central Asia Raminta Stuikyte Central and Eastern European Harm Reduction Network.
1 THE POLITICAL ECONOMY OF DRUG TRAFFICKING INTRODUCTION 1. Pervasiveness of issue 2. Challenges for research 3. Categorizing “illicit drugs”— Marijuana.
MODULE 3 Harm reduction advocacy
The effectiveness and cost-effectiveness of alcohol control policies PHE Evidence Review 31st January 2017.
Addressing Drug Use Together Through a Health Based Approach:
Community Action on Harm Reduction (CAHR) Programme
Syllabus Content Health promotion approaches and strategies
Decriminalisation Policy and the role of the CDT
Combating Drug Abuse in Montenegro
Human Dignity and Harm Reduction
Presentation transcript:

Local Pass Conference Innovative Local Approaches towards New Trends in Psychoactive Substance Use “Time to Rethink our Policy on Drugs - Effective Drug Policy Responses: the Czech Experience” Pavel Bem, MD. National Drug Commission, Czech Republic Global Commission on Drug Policy

„Opportunities and risks stay so close together…“

50 Years of World’s Experience of Combating Illicit Drugs  International cooperation in supply reduction  Crop eradication  Policies based on balanced approach between repression and prevention  Role of primary prevention/health education  Treatment and rehabilitation  Focus at urban policies

50 years of wishful thinking

Negative Results: Supply reduction failed  Supply of illicit opioids has increased 400% in last 30 years  75% decrease of heroin black market price  900% increase in heroin purity  US budget increase in war on drugs: 600% (United Nations Office on Drug and Crime, 2010) No effect on supply reduction side

Negative Results: ”Balanced” drug policies failed  Drug policy “driven” HIV epidemics, mortality  Policy “driven” HCV epidemics, morbidity  Missing balance in total expenditures: “supply vs. demand” 80% vs. 20%  Failure in assessment of evidence based approach 20% vs. 80%  Failure of national as well as supranational organizations in effective response Unintended negative consequences

Mustang: Ghar, Ghiling Gompa, 9-10th cent. “Unintended negative consequences”: Overall cost is to high…

We act only on the “surface” of the problem… BUT…

Positive Results: Demand and harm reduction works  Reducing HIV prevalence among PDU’s  Reducing HCV prevalence among PDU’s  Reducing hidden population of PDU’s  Reducing mortality among PDU’s  Reducing morbidity among PDU’s  Reducing not only public health risks, but overall social and economic costs

The need for paradigm change  Acceptance of failures  Understanding of best practices  The role of supranational authorities: Active leadership (Latin America + Europe…) l

The need for paradigm change  Prague: case study  Czech experience  Global Commission on Drug Policy

Prague Drug Policy Design  Pragmatic approach  Realistic attitude  Data based design  Balanced policy and measurable outcomes

Prague Drug Policy Design  Balance between public health and safety  Economy driven drug policy  Evidence based interventions  Police does it’s job on drug supply side  Demand and harm reduction services  Measurable outcomes (HIV, HCV, morbidity)

Prague Drug Policy Design  Availability of needles and syringes  Availability of services + outreach  Methadone + Buprenorphine + …  Non-punitive legal framework (possession is not legal offence)

HIV prevalence among IUDs in Europe

Drug Overdoses–EU Countries

Where are the benefits?  Low proportion of hidden population (< 30%)  Low mortality rate  Low prevalence of HIV among PDU’s-IVDU  Manageable morbidity rates  Manageable dynamics  Reduced public health risks  Acceptable economic and social costs 14

BUT…

We behave in simplistic way with no respect to human diversity and human rights (Papua, 2003)

New Penal Code: 1998 Penalizing possession Czech Republic case study

PAD: Impact Analysis Project of the New Drug Legislation Complex Cost and Benefit Analysis (5 major studies and 20 sub studies): 1. Secondary analysis of school surveys 2. Prevalence study of problem drug use in the CR 3. Economic and social cost of illegal drug use in the CR 4. Qualitative study among illicit drug users 5. Cost and benefit analysis of the implementation of penalization of possession of illicit drugs for personal use

Research Methodology  Combination of quantitative and qualitative methods  Measuring the direct as well as indirect costs  Interdisciplinary research team  Supervised by Florida State University, School of Criminal Justice  Granted by the National Drug Commission

Main Hypothesis  1. Availability of Illicit Drugs Will Decrease  2. Use of Illicit Drugs Will Decrease  3. Incidence of Illicit Drug Use Will Decrease  4. Negative Health Indicators Will Not Increase  5. Social Costs Related to Drug Abuse Will Not Increase After Introduction of a Penalty of Possession for Personal Use

Results  All hypothesis were rejected in 3 years study  No positive impact of the criminalization law at all Lead to Decriminalization Act 2008  Evidence based additional costs for public budgets

Recommendations Prague Declaration, No size fits all 2.Realism is the key 3.Human rights apply to ill people in particular 4.Public health and public safety concerns must not be seen as contradictory 5.Evidence based decision only 6.Evaluation and monitoring 7.Constant and improving mutual information flow

1. No size fits all  Innovative and effective interventions at the local level that have responded to local developments in the drug situation have triggered most of the advances in drug treatment, prevention, harm reduction as well as law enforcement. 4/23/2015 DC&D II Conference - PrgDecl 28

2. Realism is the “key”  A drug-free world is an unrealistic idea. It is a harmful concept if set as an ultimate goal, like other utopias that has been set in history.  It is beneficial and realistic to aim to diminish the harms related to drug trafficking and use as much as possible: through reducing the non- medical consumption of drugs and thus the total volume of related risks by means of prevention & treatment. 4/23/2015 DC&D II Conference - PrgDecl 29

3. Human rights apply to ill people in particular  Drug addiction is a disease defined by the World Health Organization.  There is no scientific justification and no ethical principle to support the criminalization of a disease or citizens being deprived of their human rights because they are ill. 4/23/2015 DC&D II Conference - PrgDecl 30

4. Public health and public safety concerns must not be seen as contradictory  Both public health and public safety efforts share the same ultimate goal in the field of drugs: to minimize the adverse consequences related to drug trafficking and use as much as possible.  The „balancing“ of the two is a simplistic concept; mixing is probably closer to the real world scenario. 4/23/2015DC&D II Conference - PrgDecl 31

5. Evidence-based decisions only  There is no doubt that the values of individual nations and communities should be reflected.  However, every such decision-making process should be firmly rooted in the evidence gathered by scientific, replicable and controllable methods.  Never ever should be based solely on beliefs, ideologies and/or wishful thinking. 4/23/2015DC&D II Conference - PrgDecl 32

6. Evaluation and monitoring  The monitoring and evaluation of interventions is widely recognised as a condition sine qua non for the successful implementation of any intervention, programme or policy.  Only those drug policies that involve evaluation as an inherent component can be constantly improved.  Monitoring in its wider sense – both of the implementation of drug policies and of the drug situation per se – is a prerequisite for any evaluation. 4/23/2015DC&D II Conference - PrgDecl 33

7. Constant mutual information flows between local, national and international levels through a common voice  The assessment, evaluation and development of national and international norms should be increasingly seen and influenced from the local perspective.  Such a process may be fostered, for example, by the creation of a global platform for networks of cities that are dealing with drug policies and that already exist in countries and/or regions. 4/23/2015DC&D II Conference - PrgDecl 34

Drug Policies at Crossroad Conclusions: 1.War on drugs has failed: Need for “rebalancing action” in drug policies design

Drug Policies at Crossroad Conclusions: 2.Need for wider implementation of cost effective public health measures: Harm reduction services especially at areas of high risk

Drug Policies at Crossroad Conclusions: 3.Decriminalization of drug possession and drug consumption worldwide

Drug Policies at Crossroad Conclusions: 4.Reallocation of drug budget priorities

The need for paradigm change  Growing awareness internationally (Global Commission on Drug Policy: former presidents, prime ministers, UN officials, intellectuals…)  Vienna high level meeting: CND 2014 (EU Action Plan on Drugs , action #5]  UNGASS 2016

“ Wishful thinking” is still prevailing among many politicians, decision makers as well as media

k Thank you for your attention